Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
POAG
MCID: GLC092
MIFTS: 62

Glaucoma, Primary Open Angle (POAG)

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Glaucoma, Primary Open Angle

About this section

MalaCards integrated aliases for Glaucoma, Primary Open Angle:

Name: Glaucoma, Primary Open Angle 57 73 37 71
Primary Open Angle Glaucoma 12 36 29 54 6 15
Glaucoma 1, Open Angle, E 57 73 29 13 6 71
Poag 57 73
Adult-Onset Primary Open Angle Glaucoma 73
Primary Open Angle Glaucoma 1e 73
Glaucoma, Open Angle, Primary 39
Chronic Simple Glaucoma 12
Glc1e 73

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant


HPO:

31
glaucoma, primary open angle:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1070
OMIM® 57 137760
KEGG 36 H00612
ICD9CM 34 365.11
MeSH 44 D005902
NCIt 50 C35394
SNOMED-CT 67 77075001
ICD10 32 H40.11
SNOMED-CT via HPO 68 263681008 57190000
UMLS 71 C0339573 C1842026
Sources

Summaries for Glaucoma, Primary Open Angle

About this section
UniProtKB/Swiss-Prot : 73 Glaucoma 1, open angle, E: A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place.
Glaucoma, primary open angle: A complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes.

MalaCards based summary : Glaucoma, Primary Open Angle, also known as primary open angle glaucoma, is related to glaucoma 3, primary congenital, a and glaucoma 1, open angle, d. An important gene associated with Glaucoma, Primary Open Angle is OPTN (Optineurin), and among its related pathways/superpathways are Ribosome biogenesis in eukaryotes and Elastic fibre formation. The drugs Latanoprost and Timolol have been mentioned in the context of this disorder. Affiliated tissues include Eye, endothelial and retina, and related phenotypes are myopia and open angle glaucoma

Disease Ontology : 12 An open-angle glaucoma that is characterized by the absence of any apparent obstruction of aqueous outflow through the trabecular meshwork with gonioscopy, but often with elevated intraocular pressure.

OMIM® : 57 Quigley (1993) reviewed adult-onset primary open angle glaucoma, which combines a particular abnormal appearance of the optic disc (optic nerve head) with a slowly progressive loss of visual sensitivity. Many patients with glaucoma have intraocular pressures above the normal range, although this cannot be considered part of the definition of the disease, since some patients have normal intraocular pressures. Changes in the optic disc, either inherited or acquired, contribute to the development of the disorder, which leads to visual loss from increasing nerve fiber layer atrophy. Quigley et al. (1994) stated that POAG should be reviewed as a multifactorial disorder. (137760) (Updated 05-Mar-2021)

KEGG : 36 Primary open angle glaucoma (POAG) is the most prevalent form of glaucoma, and a major cause of irreversible blindness. POAG is often accompanied by ocular hypertension and characterized by progressive loss of retinal ganglion cells, atrophy of the optic nerve, and visual field loss. To date, at least 20 genetic loci for POAG have been reported. And four causative genes (CYP1B1, MYOC, OPTN, and WDR36) are identified from these loci. In addition, recently, heterozygous NTF4 mutation was associated with the phenotype in a small percentage of patients.

Sources

Related Diseases for Glaucoma, Primary Open Angle

About this section

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Primary Open Angle, C
Glaucoma 1, Open Angle, D Glaucoma 1, Open Angle, F
Glaucoma 1, Open Angle, B Glaucoma 1, Open Angle, J
Glaucoma 1, Open Angle, K Glaucoma 1, Open Angle, I
Glaucoma 1, Open Angle, G Glaucoma 1, Open Angle, M
Glaucoma 1, Open Angle, N Glaucoma 1, Open Angle, H
Glaucoma 1, Open Angle, O

Diseases related to Glaucoma, Primary Open Angle via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 glaucoma 3, primary congenital, a 33.2 WDR36 OPTN MYOC LTBP2 CYP1B1
2 glaucoma 1, open angle, d 33.2 OPTN MYOC LTBP2 LOC108903148 CYP1B1 CARD10
3 glaucoma 1, open angle, a 33.2 OPTN MYOC CYP1B1
4 early-onset glaucoma 32.9 MYOC CYP1B1
5 myopia 32.2 WDR36 TGFB2 SIX6 MYOC LTBP2 CRYAA
6 eye disease 31.9 TGFB2 OPTN MYOC CYP1B1 CRYAA ABCA4
7 macular degeneration, age-related, 1 31.6 TGFB2 MYOC LOXL1 ELN CRYAA ABCA4
8 intraocular pressure quantitative trait locus 31.5 WDR36 TMCO1 TGFB2 OPTN MYOC LTBP2
9 ocular hypertension 31.3 TMCO1 TGFB2 OPTN MYOC CRYAA
10 exfoliation syndrome 31.3 LTBP2 LOXL1 GSTM1 ELN
11 neovascular glaucoma 31.3 TGFB2 MYOC CRYAA
12 steroid-induced glaucoma 31.3 WDR36 TGFB2 MYOC ELN CYP1B1 CRYAA
13 open-angle glaucoma 31.3 WDR36 TMCO1 TGFB2 SIX6 OPTN MYOC
14 leber hereditary optic neuropathy, modifier of 31.3 WDR36 MYOC CRYAA ABCA4
15 glaucoma-related pigment dispersion syndrome 31.2 WDR36 TMCO1 SIX6 OPTN MYOC LOXL1
16 yemenite deaf-blind hypopigmentation syndrome 31.2 OPTN ABCA4
17 chronic closed-angle glaucoma 31.1 TGFB2 MYOC LOXL1 CAV2
18 corneal edema 31.1 MYOC LTBP2 CYP1B1
19 optic nerve disease 31.1 WDR36 OPTN MYOC ELN CRYAA
20 keratitis, hereditary 31.0 MYOC CYP1B1 CRYAA
21 optic nerve hypoplasia, bilateral 30.9 TMCO1 SIX6 MYOC ABCA4
22 primary congenital glaucoma 30.9 WDR36 OPTN MYOC LTBP2 LOXL1 CYP1B1
23 glaucoma 3, primary infantile, b 30.8 LTBP2 CYP1B1
24 primary angle-closure glaucoma 30.8 OPTN MYOC CYP1B1
25 retinal disease 30.8 OPTN MYOC CRYAA ABCA4
26 pathologic nystagmus 30.7 SIX6 CRYAA ABCA4
27 acute closed-angle glaucoma 30.7 OPTN MYOC CYP1B1
28 cataract 30.7 TGFB2 SIX6 LOXL1 GSTM1 CRYAA
29 glaucoma, normal tension 30.7 WDR36 TMCO1 SIX6 OPTN MYOC LOXL1
30 juvenile glaucoma 30.5 WDR36 OPTN MYOC LTBP2 LOXL1 CYP1B1
31 glaucoma 1, open angle, j 11.6
32 glaucoma 1, open angle, f 11.5
33 glaucoma 1, open angle, k 11.5
34 glaucoma 1, open angle, p 11.2
35 glaucoma 1, open angle, g 11.1
36 glaucoma 1, open angle, o 11.0
37 refractive error 10.8
38 senile cataract 10.6
39 3-methylglutaconic aciduria, type iii 10.6
40 retinal vascular disease 10.6
41 neuropathy 10.6
42 scotoma 10.6
43 traumatic glaucoma 10.6 TMCO1 MYOC LTBP2 LOXL1 CYP1B1
44 amyotrophic lateral sclerosis 12 with or without frontotemporal dementia 10.6 OPTN LOC108903148 CAMK1D
45 excessive tearing 10.6 WDR36 MYOC LTBP2 CYP1B1
46 hydrophthalmos 10.5 WDR36 MYOC LTBP2 CYP1B1
47 microphthalmia, isolated 2 10.5 WDR36 MYOC CYP1B1
48 megalocornea 10.5 WDR36 MYOC LTBP2 CYP1B1
49 amyotrophic lateral sclerosis type 12 10.5 OPTN LOC108903148 CRYAA CAMK1D
50 phimosis 10.5 ELN CYP1B1 CRYAA

Comorbidity relations with Glaucoma, Primary Open Angle via Phenotypic Disease Network (PDN):


Chronic Closed-Angle Glaucoma Hypertension, Essential
Ocular Hypertension Ocular Hypotension
Open-Angle Glaucoma Residual Stage of Open Angle Glaucoma

Graphical network of the top 20 diseases related to Glaucoma, Primary Open Angle:



Diseases related to Glaucoma, Primary Open Angle
Sources

Symptoms & Phenotypes for Glaucoma, Primary Open Angle

About this section

Human phenotypes related to Glaucoma, Primary Open Angle:

31
# Description HPO Frequency HPO Source Accession
1 myopia 31 HP:0000545
2 open angle glaucoma 31 HP:0012108

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Eyes:
myopia
open angle glaucoma

Misc:
more frequent among african americans

Clinical features from OMIM®:

137760 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Glaucoma, Primary Open Angle:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 ABCA4 CAMK1D CYP1B1 LOXL1 LTBP2 MYOC
Sources

Drugs & Therapeutics for Glaucoma, Primary Open Angle

About this section

Drugs for Glaucoma, Primary Open Angle (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
2
Timolol Approved Phase 4 26839-75-8 33624 5478
3
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
4
Brinzolamide Approved Phase 4 138890-62-7 68844
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
7
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
8
tannic acid Approved Phase 4 1401-55-4
9
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
10
Travoprost Approved Phase 4 157283-68-6 5282226
11 Antihypertensive Agents Phase 4
12 Dextrans Phase 4
13 Plasma Substitutes Phase 4
14 Blood Substitutes Phase 4
15 Anticoagulants Phase 4
16 Lubricant Eye Drops Phase 4
17 Anti-Infective Agents Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Benzalkonium Compounds Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Hormone Antagonists Phase 4
22 glucocorticoids Phase 4
23 Hormones Phase 4
24 Antineoplastic Agents, Hormonal Phase 4
25 Gastrointestinal Agents Phase 4
26 Antiemetics Phase 4
27 Anesthetics Phase 4
28 Adrenergic alpha-Agonists Phase 4
29 Brimonidine Tartrate Phase 4 70359-46-5
30 Adrenergic Agonists Phase 4
31 cefuroxime axetil Phase 4
32 Pharmaceutical Solutions Phase 4
33 Ophthalmic Solutions Phase 4
34
Adenosine Approved, Investigational Phase 3 58-61-7 60961
35
Papaverine Approved, Investigational Phase 2, Phase 3 58-74-2, 61-25-6 4680
36
Betaxolol Approved, Investigational Phase 3 659-18-7, 63659-18-7 2369
37 Moxaverine Investigational Phase 2, Phase 3 10539-19-2
38 Analgesics Phase 3
39 Vasodilator Agents Phase 3
40 Phosphodiesterase Inhibitors Phase 2, Phase 3
41 Parasympatholytics Phase 2, Phase 3
42 Adrenergic beta-1 Receptor Antagonists Phase 3
43 Sympatholytics Phase 3
44
Fluorouracil Approved Phase 2 51-21-8 3385
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
46
Choline Approved, Nutraceutical Phase 2 62-49-7 305
47
Epigallocatechin Experimental, Investigational Phase 1, Phase 2 970-74-1 72277
48
Epigallocatechin gallate Investigational Phase 1, Phase 2 989-51-5 65064
49
Tramiprosate Investigational Phase 2 3687-18-1
50 Neuroprotective Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 293)
# Name Status NCT ID Phase Drugs
1 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent Unknown status NCT01252914 Phase 4
2 Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
3 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
4 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
5 Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Completed NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
6 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252888 Phase 4
7 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252862 Phase 4
8 A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) Completed NCT02863705 Phase 4 brimonidine tartrate/timolol malate Ophthalmic Solution;bimatoprost ophthalmic solution 0.01%
9 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
10 Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
11 Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
12 A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
13 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance Completed NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
14 A Study of LUMIGAN® RC in the Clinical Setting Completed NCT01833741 Phase 4 Bimatoprost 0.01%
15 Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects Completed NCT02006693 Phase 4
16 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
17 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
18 Phase 4 Study to Evaluate Efficacy And Safety of Pneumatic Trabeculoplasty (PNT) in Subjects Affected by Primary Open Angle Glaucoma Completed NCT01540331 Phase 4
19 Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs Completed NCT00675207 Phase 4 Brimonidine purite 0.15%;Dorzolamide 2%;Brinzolamide 1%
20 Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
21 Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Completed NCT03104621 Phase 4 Benzalkonium chloride (BAK);0.0015% tafluprost
22 Multicentric Study to Evaluate the Efficacy and Tolerability of an Innovative Formulation of Benzalkonium Chloride-free Latanoprost in Patients With Primary Open-Angle Glaucoma Completed NCT03331770 Phase 4 Latanoprost Ophthalmic Product
23 Ocular Surface Conditions in Asian Glaucoma Patients With Existing Corneal Disorders Switching From Preserved Prostaglandin Analogues Monotherapy to Preservative-free Tafluprost Completed NCT04654611 Phase 4 preservative free tafluprost 0.0015%
24 A Crossover, Double-Masked Comparison Investigating the 24-Hour Intraocular Pressure Control With the Travoprost/Timolol Fixed Combination Versus Travoprost, When Both Are Given in the Evening, in Subjects With Primary Open-Angle Glaucoma Completed NCT00444184 Phase 4 Travoprost/timolol fixed combination, travoprost
25 A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
26 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
27 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
28 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
29 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
30 Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.
31 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
32 Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma Completed NCT03966560 Phase 4 Brimonidine Tartrate;Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops;Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension;Travoprost and Timolol;Bimatoprost and Timolol;Latanoprost
33 Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolol Fixed Combination (DTFC) Compared With the Brimonidine/Timolol Fixed Combination (BTFC) in Subjects With Primary Open-angle Glaucoma Completed NCT00972257 Phase 4 treatment with dorzolamide/timolol;treatment with brimonidine/timolol
34 An Open, Non-randomized Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma on Tear Film Thickness Completed NCT03204487 Phase 4 Tafluprost 15µg/ml
35 The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
36 A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma Completed NCT00913029 Phase 4 latanoprost/timolol
37 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
38 Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy Completed NCT00143208 Phase 4 Xalacom
39 Randomized, Controlled Treatment With an Intracanalicular Dexamethasone (0.4mg) Insert Following Cataract Surgery With IOL Combined With MIGS, Specifically iStent, iStent Inject or KDB in Patients With POAG or Ocular Hypertension (OHTN) Recruiting NCT04465864 Phase 4 Intracanalicular Dexamethasone, 0.4 mg insert
40 Efficacy and Safety of Latanoprost/Timolol Fixed Combination Dosed Twice Daily Compared to Once Daily in Patients With Primary Open Angle Glaucoma Recruiting NCT04098861 Phase 4 Latanoprost/Timolol
41 A Prospective Randomized Clinical Trial Comparing Three Delivery Methods of Mitomycin-C for Trabeculectomy Surgery: Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Topical Application (Conventional Use) During Trabeculectomy Surgery Recruiting NCT03875911 Phase 4 Mitomycin C
42 Comparing the Effectiveness of Phacoemulsification + ECP Laser and Phacoemulsification Alone for the Treatment of Open Angle Glaucoma in Patients With Cataract - a Randomised Controlled Trial Not yet recruiting NCT04295122 Phase 4
43 Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination to the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination, in Primary Open Angle Glaucoma or Ocular Hypertension Patients. Not yet recruiting NCT04702789 Phase 4 Dorzolamide-timolol-brimonidine and latanoprost;Dorzolamide-timolol and latanoprost
44 Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension Terminated NCT02047630 Phase 4 Generic latanoprost;Brand-name latanoprost
45 Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension Terminated NCT00471068 Phase 4 Travatan;Cosopt;Placebo (Timolol Vehicle)
46 A 8-Week, Randomized, Double-Masked, Parallel Group, Phase III Study Comparing The Efficacy And Safety Of Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH). Completed NCT00383019 Phase 3 Xalacom (KP2035);Xalatan
47 Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension Completed NCT00230763 Phase 3 LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
48 Phase III Multi-center, Randomized, Double-masked, Active- and Placebo-controlled Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma Completed NCT02565173 Phase 3 trabodenoson 4.5% BID;trabodenoson 6.0% QD;trabodenoson 3.0% QD;timolol 0.5% BID;placebo BID
49 A Randomized, Multicenter, Parallel-Group, Observer-Masked, Phase 3 Study to Compare the Safety and Efficacy of T-2345 Ophthalmic Solution to Xalatan (Latanoprost 0.005%) in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension Completed NCT02059278 Phase 3 T-2345;Xalatan
50 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination Completed NCT00331240 Phase 3 travoprost/timolol fixed combination;placebo (artificial tears)

Search NIH Clinical Center for Glaucoma, Primary Open Angle

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glaucoma, Primary Open Angle cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glaucoma, Primary Open Angle:
Renexus (NT-501), CNTF-secreting cells for treatment of retinal diseases
Embryonic/Adult Cultured Cells Related to Glaucoma, Primary Open Angle:
Human retinal stem cells secreting CNTF PMIDs: 16805711 17508034 16505355 23049090 15684670 12581701 15223826 18830926
Sources

Genetic Tests for Glaucoma, Primary Open Angle

About this section

Genetic tests related to Glaucoma, Primary Open Angle:

# Genetic test Affiliating Genes
1 Primary Open Angle Glaucoma 29 OPTN
2 Primary Open Angle Glaucoma (adult Onset) 29
3 Glaucoma 1, Open Angle, E 29
Sources

Anatomical Context for Glaucoma, Primary Open Angle

About this section

MalaCards organs/tissues related to Glaucoma, Primary Open Angle:

40
Eye, Endothelial, Retina, Brain, Cortex, Heart, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glaucoma, Primary Open Angle:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Ganglion Cell Layer Mature Ganglion Cells Affected by disease
Sources

Publications for Glaucoma, Primary Open Angle

About this section

Articles related to Glaucoma, Primary Open Angle:

(show top 50) (show all 7455)
# Title Authors PMID Year
1
Adult-onset primary open-angle glaucoma caused by mutations in optineurin. 61 57 6
11834836 2002
2
Altered nitric oxide system in patients with open-angle glaucoma. 57 61
17420369 2007
3
Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. 61 57
17325163 2007
4
Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. 57 61
15728543 2005
5
CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma. 61 6
15342693 2004
6
Reduction of posterior pole retinal thickness in glaucoma detected using the Retinal Thickness Analyzer. 61 57
15019374 2004
7
Oxidative stress markers in aqueous humor of glaucoma patients. 61 57
14700645 2004
8
Heritability of risk factors for primary open-angle glaucoma: the Beaver Dam Eye Study. 61 57
14691154 2004
9
Effects of TGF-beta2 in perfused human eyes. 61 57
14691167 2004
10
A genome-wide scan for primary open-angle glaucoma (POAG): the Barbados Family Study of Open-Angle Glaucoma. 61 57
12616399 2003
11
T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. 57 61
11292402 2001
12
Absence of trabecular meshwork-inducible stretch response (TISR)/oculomedin gene and proximal promoter mutation in primary open angle glaucoma patients. 57 61
11129344 2000
13
Genome-wide scan for adult onset primary open angle glaucoma. 57 61
10767336 2000
14
Adult-onset primary open angle glaucoma does not localize to chromosome 2cen-q13 in North American families. 57 61
9748694 1998
15
Localization of the fourth locus (GLC1E) for adult-onset primary open-angle glaucoma to the 10p15-p14 region. 57 61
9497264 1998
16
Recent advances in molecular genetics of glaucomas. 61 57
9300658 1997
17
Models of open-angle glaucoma prevalence and incidence in the United States. 57 61
9008633 1997
18
The distinction between juvenile and adult-onset primary open-angle glaucoma. 57 61
8554064 1996
19
Genetic defect in cortisol metabolism in primary open angle glaucoma. 57 61
3842204 1985
20
Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. 57
25819459 2015
21
Prevention of nocturnal elevation of intraocular pressure by gene transfer of dominant-negative RhoA in rats. 57
25412195 2015
22
Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. 57
21532571 2011
23
Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. 6
18470941 2008
24
Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. 57
17988642 2008
25
Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. 57
17591886 2007
26
Presence of an established calcification marker in trabecular meshwork tissue of glaucoma donors. 57
17591888 2007
27
Heritable features of the optic disc: a novel twin method for determining genetic significance. 57
17525172 2007
28
A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants. 57
17389490 2007
29
High myopia and glaucoma susceptibility the Beijing Eye Study. 57
17123613 2007
30
Endothelin B receptor in human glaucoma and experimentally induced optic nerve damage. 57
16682595 2006
31
Model of endothelin-1-induced chronic optic neuropathy in rat. 57
14691166 2004
32
Ganglion cell losses underlying visual field defects from experimental glaucoma. 57
10476789 1999
33
Molecular genetics of the glaucomas: mapping of the first five "GLC" loci. 57
9012399 1997
34
Risk factors for the development of glaucomatous visual field loss in ocular hypertension. 57
8185522 1994
35
Open-angle glaucoma. 57
8455668 1993
36
Racial differences in intraocular tension and glaucoma surgery. 57
7387780 1980
37
Current concepts in ophthalmology: the glaucomas. 57
351398 1978
38
Twin heritability study of the effect of corticosteroids on intraocular pressure. 57
5065285 1972
39
Ocular pressure and aqueous outflow facility in siblings. 57
5670691 1968
40
The heritable nature of dexamethasone-induced ocular hypertension. 57
5900502 1966
41
THE INHERITANCE OF GLAUCOMA. A PEDIGREE OF FAMILIAL GLAUCOMA. 57
14310076 1965
42
Primary open angle glaucoma due to T377M MYOC: Population mapping of a Greek founder mutation in Northwestern Greece. 61 54
20390039 2010
43
Variable clinical spectrum of the myocilin Gln368X mutation in a Dutch family with primary open angle glaucoma. 54 61
20021252 2010
44
[Genetic variants of CYP1B1 and WDR36 in the patients with primary congenital glaucoma and primary open angle glaucoma from Saint-Petersburg]. 54 61
20198978 2009
45
Autosomal recessive primary open angle glaucoma (POAG) in beagles is not associated with mutations in the myocilin (MYOC) gene. 54 61
19225800 2009
46
Overexpression of myocilin in the Drosophila eye activates the unfolded protein response: implications for glaucoma. 54 61
19148291 2009
47
Gillies lecture: dissecting glaucoma: understanding the molecular risk factors. 61 54
18925913 2008
48
Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma. 61 54
18307994 2008
49
Screening of common CYP1B1 mutations in Iranian POAG patients using a microarray-based PrASE protocol. 54 61
19096718 2008
50
Recurrent Myocilin Asn480Lys glaucoma causative mutation arises de novo in a family of Andean descent. 61 54
18303389 2008
Sources

Variations for Glaucoma, Primary Open Angle

About this section

ClinVar genetic disease variations for Glaucoma, Primary Open Angle:

6 (show top 50) (show all 135)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LOC108903148 NM_001008212.2(OPTN):c.148G>A (p.Glu50Lys) SNV Pathogenic 7096 rs28939688 10:13151270-13151270 10:13109270-13109270
2 OPTN OPTN, 2-BP INS, 691AG Insertion Pathogenic 7097
3 LOC108903148 NM_001008212.2(OPTN):c.293T>A (p.Met98Lys) SNV Pathogenic 7099 rs11258194 10:13152400-13152400 10:13110400-13110400
4 MYOC NM_000261.2(MYOC):c.1111T>C (p.Tyr371His) SNV Pathogenic 242274 rs878854408 1:171605469-171605469 1:171636329-171636329
5 LOC108903148 NM_001008212.2(OPTN):c.158_161dup (p.Lys55fs) Duplication Pathogenic 576203 rs1564354968 10:13151279-13151280 10:13109279-13109280
6 LOC108903148 NC_000010.11:g.(?_13109123)_(13183100_?)del Deletion Pathogenic 583651 10:13151123-13225100 10:13109123-13183100
7 CAMK1D NC_000010.10:g.(?_12833157)_(13178866_?)del Deletion Pathogenic 584050 10:12833157-13178866
8 OPTN NM_001008212.2(OPTN):c.381_382insAG (p.Asp128fs) Insertion Pathogenic 647662 rs774258585 10:13154464-13154465 10:13112464-13112465
9 OPTN NC_000010.11:g.(?_13109113)_(13112645_?)del Deletion Pathogenic 832940 10:13151113-13154645
10 LOC108903148 NC_000010.11:g.(?_13109103)_(13136886_?)del Deletion Pathogenic 529764 10:13151103-13178886 10:13109103-13136886
11 OPTN NC_000010.11:g.(?_13116257)_(13116350_?)del Deletion Pathogenic 831344 10:13158257-13158350
12 OPTN NM_001008212.2(OPTN):c.1634G>A (p.Arg545Gln) SNV Pathogenic 7098 rs75654767 10:13178766-13178766 10:13136766-13136766
13 CYP1B1 NM_000104.3(CYP1B1):c.241T>A (p.Tyr81Asn) SNV Pathogenic 7744 rs9282671 2:38302291-38302291 2:38075148-38075148
14 CARD10 NM_014550.4(CARD10):c.1210C>T (p.Arg404Trp) SNV risk factor 224915 rs750643216 22:37902372-37902372 22:37506365-37506365
15 CARD10 NM_014550.4(CARD10):c.635G>A (p.Arg212His) SNV risk factor 224912 rs1057519378 22:37912044-37912044 22:37516037-37516037
16 CARD10 NM_014550.4(CARD10):c.2485C>T (p.Arg829Trp) SNV risk factor 224916 rs201794655 22:37888801-37888801 22:37492794-37492794
17 CARD10 NM_014550.4(CARD10):c.983C>T (p.Ala328Val) SNV risk factor 224913 rs139006752 22:37904616-37904616 22:37508609-37508609
18 CARD10 NM_014550.4(CARD10):c.1024G>A (p.Val342Met) SNV risk factor 224914 rs200148764 22:37904575-37904575 22:37508568-37508568
19 LTBP2 NM_000428.3(LTBP2):c.1484G>A (p.Arg495Gln) SNV Likely pathogenic 126950 rs137854858 14:75017969-75017969 14:74551266-74551266
20 LTBP2 NM_000428.3(LTBP2):c.3571G>A (p.Glu1191Lys) SNV Likely pathogenic 126954 rs137854862 14:74975388-74975388 14:74508685-74508685
21 LTBP2 NM_000428.3(LTBP2):c.4250A>G (p.Gln1417Arg) SNV Likely pathogenic 126955 rs137854863 14:74971805-74971805 14:74505102-74505102
22 LTBP2 NM_000428.3(LTBP2):c.4912G>A (p.Val1638Met) SNV Likely pathogenic 126958 rs137854860 14:74969614-74969614 14:74502911-74502911
23 MYOC NM_000261.2(MYOC):c.1102C>T (p.Gln368Ter) SNV Likely pathogenic 7949 rs74315329 1:171605478-171605478 1:171636338-171636338
24 OPTN NM_001008212.2(OPTN):c.1634G>A (p.Arg545Gln) SNV Conflicting interpretations of pathogenicity 7098 rs75654767 10:13178766-13178766 10:13136766-13136766
25 OPTN NM_001008212.2(OPTN):c.682C>T (p.His228Tyr) SNV Uncertain significance 934500 10:13160943-13160943 10:13118943-13118943
26 OPTN NM_001008212.2(OPTN):c.*222G>C SNV Uncertain significance 877764 10:13179088-13179088 10:13137088-13137088
27 OPTN NM_001008212.2(OPTN):c.*335C>T SNV Uncertain significance 877765 10:13179201-13179201 10:13137201-13137201
28 LOC108903148 NM_001008212.2(OPTN):c.359G>A (p.Arg120Lys) SNV Uncertain significance 878705 10:13152466-13152466 10:13110466-13110466
29 OPTN NM_001008212.2(OPTN):c.398G>A (p.Arg133Lys) SNV Uncertain significance 878706 10:13154481-13154481 10:13112481-13112481
30 OPTN NM_001008212.2(OPTN):c.-184C>G SNV Uncertain significance 879254 10:13142282-13142282 10:13100282-13100282
31 OPTN NM_001008212.2(OPTN):c.-172G>A SNV Uncertain significance 879255 10:13142294-13142294 10:13100294-13100294
32 OPTN NM_001008212.2(OPTN):c.1243-9C>A SNV Uncertain significance 878758 10:13169736-13169736 10:13127736-13127736
33 OPTN NM_001008212.2(OPTN):c.1442C>T (p.Ala481Val) SNV Uncertain significance 447910 rs377219791 10:13174107-13174107 10:13132107-13132107
34 OPTN NM_001008212.2(OPTN):c.*631A>G SNV Uncertain significance 878794 10:13179497-13179497 10:13137497-13137497
35 OPTN NM_001008212.2(OPTN):c.*1111A>C SNV Uncertain significance 879768 10:13179977-13179977 10:13137977-13137977
36 LOC108903148 NM_001008212.2(OPTN):c.-9A>G SNV Uncertain significance 880441 10:13151114-13151114 10:13109114-13109114
37 LOC108903148 NM_001008212.2(OPTN):c.17T>G (p.Leu6Arg) SNV Uncertain significance 880442 10:13151139-13151139 10:13109139-13109139
38 OPTN NM_001008212.2(OPTN):c.1242+327C>T SNV Uncertain significance 931275 10:13168366-13168366 10:13126366-13126366
39 OPTN NM_001008212.2(OPTN):c.1414T>C (p.Cys472Arg) SNV Uncertain significance 932115 10:13174079-13174079 10:13132079-13132079
40 OPTN NM_001008212.2(OPTN):c.1613G>A (p.Gly538Glu) SNV Uncertain significance 940858 10:13178745-13178745 10:13136745-13136745
41 OPTN NM_001008212.2(OPTN):c.754G>C (p.Val252Leu) SNV Uncertain significance 962957 10:13161015-13161015 10:13119015-13119015
42 LOC108903148 NM_001008212.2(OPTN):c.287G>A (p.Arg96His) SNV Uncertain significance 969108 10:13152394-13152394 10:13110394-13110394
43 OPTN NM_001008212.2(OPTN):c.*938C>G SNV Uncertain significance 299232 rs886046826 10:13179804-13179804 10:13137804-13137804
44 OPTN NM_001008212.2(OPTN):c.941A>T (p.Gln314Leu) SNV Uncertain significance 266060 rs142812715 10:13166053-13166053 10:13124053-13124053
45 OPTN NM_001008212.2(OPTN):c.963C>T (p.Ser321=) SNV Uncertain significance 299218 rs150381274 10:13166075-13166075 10:13124075-13124075
46 OPTN NM_001008212.2(OPTN):c.1402-3C>G SNV Uncertain significance 650247 rs1588452749 10:13174064-13174064 10:13132064-13132064
47 OPTN NM_001008212.2(OPTN):c.403G>A (p.Glu135Lys) SNV Uncertain significance 651429 rs140599944 10:13154486-13154486 10:13112486-13112486
48 OPTN NC_000010.11:g.(?_13118878)_(13119050_?)del Deletion Uncertain significance 832895 10:13160878-13161050
49 OPTN NM_001008211.1(OPTN):c.-408G>T SNV Uncertain significance 877641 10:13142127-13142127 10:13100127-13100127
50 LOC108903148 NM_001008212.2(OPTN):c.14C>G (p.Pro5Arg) SNV Uncertain significance 565324 rs1564354765 10:13151136-13151136 10:13109136-13109136

UniProtKB/Swiss-Prot genetic disease variations for Glaucoma, Primary Open Angle:

73
# Symbol AA change Variation ID SNP ID
1 OPTN p.His26Asp VAR_021537 rs200710076
2 OPTN p.Glu50Lys VAR_021538 rs28939688
3 OPTN p.Glu103Asp VAR_021540 rs134686580
4 OPTN p.His486Arg VAR_021546 rs373425395

Sources

Expression for Glaucoma, Primary Open Angle

About this section
Search GEO for disease gene expression data for Glaucoma, Primary Open Angle.
Sources

Pathways for Glaucoma, Primary Open Angle

About this section

Pathways related to Glaucoma, Primary Open Angle according to KEGG:

36
# Name Kegg Source Accession
1 Ribosome biogenesis in eukaryotes hsa03008

Pathways related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Elastic fibre formation 65
Show member pathways
 10.79 TGFB2 LTBP2 LOXL1 ELN
Sources

GO Terms for Glaucoma, Primary Open Angle

About this section

Cellular components related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.26 LTBP2 LOXL1 ELN COCH
2 collagen-containing extracellular matrix GO:0062023 9.1 TGFB2 MYOC LTBP2 LOXL1 ELN COCH

Biological processes related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen fibril organization GO:0030199 9.13 TGFB2 LOXL1 CYP1B1
2 visual perception GO:0007601 9.02 WDR36 SIX6 CYP1B1 CRYAA ABCA4
Sources

Sources for Glaucoma, Primary Open Angle

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....